GRANULES

Granules India Share Price

₹592.40 -7.65 (-1.27%)

21 Dec, 2024 18:14

SIP TrendupStart SIP in GRANULES

Start SIP

Performance

  • Low
  • ₹590
  • High
  • ₹613
  • 52 Week Low
  • ₹365
  • 52 Week High
  • ₹721
  • Open Price₹603
  • Previous Close₹600
  • Volume3,942,427

Investment Returns

  • Over 1 Month + 7.19%
  • Over 3 Month + 9.72%
  • Over 6 Month + 25.43%
  • Over 1 Year + 57.47%
SIP Lightning

Smart Investing Starts Here Start SIP with Granules India for Steady Growth!

Invest Now

Granules India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 29.5
  • PEG Ratio
  • 1.2
  • Market Cap Cr
  • 14,365
  • P/B Ratio
  • 4.5
  • Average True Range
  • 21.2
  • EPS
  • 20.09
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 4.87
  • RSI
  • 55.59
  • MFI
  • 50.15

Granules India Financials

Granules India Technicals

EMA & SMA

Current Price
₹592.40
-7.65 (-1.27%)
pointer
  • stock-down_img
  • Bullish Moving Average 13
  • stock-up_img
  • Bearish Moving Average 3
  • 20 Day
  • ₹581.24
  • 50 Day
  • ₹577.19
  • 100 Day
  • ₹568.91
  • 200 Day
  • ₹531.96

Resistance and Support

598.3 Pivot Speed
  • R3 629.10
  • R2 620.80
  • R1 606.60
  • S1 584.10
  • S2 575.80
  • S3 561.60

What's your outlook on Granules India?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Granules India Ltd. is a pharmaceutical company specializing in the production of Active Pharmaceutical Ingredients (APIs), pharmaceutical formulations, and over-the-counter (OTC) products. It operates globally, supplying high-quality, cost-effective solutions to customers in over 60 countries.

Granules India has an operating revenue of Rs. 4,477.85 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 12% is healthy, ROE of 12% is good. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 13% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 16% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 67 which is a FAIR score but needs to improve its earnings, a RS Rating of 68 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Granules India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-06 Quarterly Results
2024-07-30 Quarterly Results
2024-05-15 Audited Results & Final Dividend
2024-01-23 Quarterly Results
2023-11-09 Quarterly Results
Date Purpose Remarks
2023-08-03 FINAL Rs.1.50 per share(150%)Final Dividend
2022-02-18 INTERIM Re.0.25 per share (25%) Third Interim Dividend
2021-11-25 INTERIM Re.0.25 per share (25%) Second Interim Dividend
2021-08-06 INTERIM Rs.0.25 per share(25%)First Interim Dividend
2021-02-09 INTERIM Rs.0.25 per share (25%) Third Interim Dividend

Granules India F&O

Granules India Shareholding Pattern

38.87%
7.86%
6.12%
19.49%
18.29%
9.37%

About Granules India

Granules India Ltd. is vertically integrated pharmaceutical company based in India, specializing in manufacturing of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), & finished dosages. Established in 1984, company has strong presence in global pharmaceutical market, supplying its products to over 300 customers in more than 60 countries. Granules India's focus on cost-efficient manufacturing, quality assurance, & regulatory compliance has enabled it to become trusted partner for leading pharmaceutical companies worldwide. company's commitment to innovation & expansion has driven its growth in highly competitive pharmaceutical industry.

With six tons of batch processing capacity, it is one of biggest PFI makers in India. Since its PFIs are made to transfer straight from drums to hoppers, it has established itself as top supplier to major international pharmaceutical corporations. 
The strategy focus on high-value formulations & drop in API sales are to blame for change in revenue contribution.

Beyond top five heritage items, company is expanding its product line; as of FY24, new products account for 25% of total sales, up from 19% in FY22.
 

View More
  • NSE Symbol
  • GRANULES
  • BSE Symbol
  • 532482
  • Chairman & Managing Director
  • Dr. Krishna Prasad Chigurupati
  • ISIN
  • INE101D01020

Similar Stocks to Granules India

Granules India FAQs

Granules India share price is ₹592 As on 21 December, 2024 | 18:00

The Market Cap of Granules India is ₹14365.3 Cr As on 21 December, 2024 | 18:00

The P/E ratio of Granules India is 29.5 As on 21 December, 2024 | 18:00

The PB ratio of Granules India is 4.5 As on 21 December, 2024 | 18:00

Consider company's market position in pharmaceutical industry & its growth prospects before investing.
 

Key metrics include revenue from key products, profit margins, & regulatory approvals.

Open Demat account with 5 Paisa Capital & post doing KYC & active account search for Granules India share, you can then put order as you prefer.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23